24/7 Market News Snapshot 12 May, 2025 – Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 12, 2025

DENVER, Colo., 12 May, 2025 (www.247marketnews.com) – (NASDAQ:TNGX) are discussed in this article.
Tango Therapeutics, Inc. (TNGX) has experienced a significant increase in stock performance, with shares opening at $1.17 and currently trading at $1.305, reflecting a robust 14.47% rise. This upward movement comes after the stock surpassed its previous close of $1.14, signaling heightened investor interest and market activity. Trading volume has reached 1.01 million shares, indicating potential for further volatility. Investors are advised to closely monitor key support levels around $1.17 and resistance points near $1.35 to gauge the sustainability of this trend.

Complementing this positive market response, Tango Therapeutics has also announced promising developments in its clinical programs alongside financial results for the first quarter ending March 31, 2025. The company is focused on advancing its lead candidate, TNG462, a PRMT5 inhibitor, which has shown potential as a best-in-class therapy. Preliminary data from the ongoing Phase 1/2 trial has been encouraging, with an anticipated comprehensive update on efficacy and safety expected in the latter half of 2025. The focus will particularly be on pancreatic and lung cancer indications.

Additionally, Tango is preparing to launch a combination trial using TNG462 in conjunction with Revolution Medicines’ RAS(ON) inhibitors, with enrollment projected for the second quarter of 2025. This strategic endeavor aims to enhance treatment options for patients suffering from pancreatic and lung cancers, informed by encouraging preclinical data.

Financially, Tango maintains a strong position with approximately $217 million in cash as of March 31, 2025, positioning the company to support its operations into early 2027. This financial stability allows for strategic investments in high-potential programs. Upcoming milestones include the initiation of the TNG456 Phase 1/2 trial targeting glioblastoma and key updates on the TNG260 trial later this year, underscoring Tango Therapeutics’ commitment to innovative cancer therapies.

Related news for (TNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.